Inophynone for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Inophynone may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed inophynone in detail.
, Studi in silico: Screening Virtual Senyawa Triterpenoid pada Canophyllum inophyllum Sebagai Kandidat Inhibitor SARS-CoV-2, Jurnal Fisika Unand, doi:10.25077/jfu.14.5.459-465.2025
Penelitian ini bertujuan untuk mengidentifikasi potensi senyawa-senyawa triterpenoid dari tamanu (Canophyllum inophyllum) sebagai inhibitor SARS-CoV-2 melalui pendekatan in-silico menggunakan molecular docking. Dipilih sepuluh senyawa triterpenoid dan diuji afinitas ikatannya terhadap main protease (Mpro) SARS-CoV-2 (PDB ID:6W63). Hasil menunjukkan bahwa empat senyawa triterpenoid, diantaranya oleanolic acid (-8.2 kcal/mol), friedelin (-8.2 kcal/mol), inophynone (-8.1 kcal/mol), dan epifriedelanol (-8.2 kcal/mol) memiliki binding affinity yang lebih rendah dibandingkan ligand alami (X77 -8.0 kcal/mol) maupun ligand pembandingnya (paxlovid), yang mengindikasikan interaksi yang lebih kuat terhadap situs aktif protein. Diantara empat kandidat, hanya oleanolic acid yang membentuk ikatan hidrogen dengan residu asam amino pada situs aktif protein, yang memperkuat kemungkinan peranannya sebagai inhibitor SARS-CoV-2. Temuan ini menunjukkan bahwa senyawa-senyawa tersebut, khususnya oleanolic acid, berpotensi dikembangkan lebih lanjut sebagai terapi Covid-19 berbasis bahan alam. Studi ini memberikan kontribusi awal dalam ekplorasi bahan alam sebagai sumber senyawa aktif untuk pengembangan terapi Covid-19 melalui pendekatan in-silico